Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)

Background/Aims: The treatment of hepatocellular carcinoma (HCC), which accounts for 90% of all liver cancers, is highly varied. The use of second-line treatments following progression on first-line atezolizumab and bevacizumab (Atez/Bev) for advanced HCC remains controversial. The aim of this stu...

Full description

Bibliographic Details

Published in:	The Turkish Journal of Gastroenterology
Main Authors:	Nargiz Majidova, Sendag Yaslıkaya, Maral Martin Mıldanoglu, Alper Coskun, Duygu Ercan Uzundal, Taha Koray Sahin, Arif Akyildiz, Sinem Akbas, Ufuk Camanlı, Elif Sahin, Huseyin Atacan, Ismail Bayrakcı, Teoman Sakalar, Ceren Mordag Cicek, Damla Gunenc, Nurullah İlhan, Olcun Umit Unal, Ozkan Alan, Buket Hamitoglu, Esra Ozen Engin, Nadiye Sever, Ali Kaan Guren, Ahmet Unsal, Murat Araz, Bulent Erdogan, Musa Barıs Aykan, Fatih Selcukbiricik, Deniz Can Guven, Nuriye Ozdemir, Ahmet Bilgehan Sahin, Ahmet Bilici, Ismail Oguz Kara, Suayip Yalcın, Osman Kostek
Format:	Article
Language:	English
Published:	Turkish Society of Gastroenterology 2025-05-01
Online Access:	https://www.turkjgastroenterol.org/en/efficacy-of-second-line-treatments-after-atezolizumab-and-bevacizumab-in-advanced-hepatocellular-carcinoma-and-related-prognostic-factors-a-multicenter-study-by-the-turkish-oncology-group-tog-137360